Paper · 34644529

Spatially confined sub-tumor microenvironments in pancreatic cancer.

Grünwald BT and 23 others. Cell, 2021. Cited by 356 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Spatially confined sub-tumor microenvironments in pancreatic cancer. Papers, record 34644529. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34644529

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Spatially confined sub-tumor microenvironments in pancreatic cancer.; PubMed
Journal: Cell; PubMed
Year: 2021; PubMed
Publication types: Journal Article, Research Support, Non-U.S. Gov't; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/34644529/; PubMed
DOI: https://doi.org/10.1016/j.cell.2021.09.022; PubMed
The journal: https://conductscience.org/library/journal-index/0413066; PubMed
Citations, by iCite: 356; iCite
Relative citation ratio, by iCite: 17.3; iCite
Revised in PubMed: 2022-01-06; PubMed

Authors24

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Grünwald BT	Barbara T
2	Devisme A	Antoine
3	Andrieux G	Geoffroy
4	Vyas F	Foram
5	Aliar K	Kazeera
6	McCloskey CW	Curtis W
7	Macklin A	Andrew
8	Jang GH	Gun Ho
9	Denroche R	Robert
10	Romero JM	Joan Miguel

1 to 10 of 24Source PubMed

See all 24 authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Pancreatic Neoplasms	Major topic
Tumor Microenvironment	Major topic
Adenocarcinoma
Cancer-Associated Fibroblasts
Carcinoma, Pancreatic Ductal
Cell Differentiation
Cell Proliferation
Epithelium
Extracellular Matrix
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Humans
Male
Middle Aged
Phenotype
Stromal Cells
Survival Analysis

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by267

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 356 citations.

PMID	Title	Journal	Year	In Papers	Source
42,953,944	Harnessing chemokines and nanocarriers to reprogram the tumor microenvironment.	Drug Deliv	2026	https://conductscience.org/library/papers/42953944	PubMed
42,928,513	NCLX Inhibition plus Ca2+ Delivery Potentiates Electroporation and Antitumor Immunity in Pancreatic Ductal Adenocarcinoma.	Adv Sci (Weinh)	2026	https://conductscience.org/library/papers/42928513	PubMed
42,919,442	Oncogenic RAS as an adaptive signaling ecosystem: context-dependent vulnerabilities and resistance-informed therapeutic design.	Exp Hematol Oncol	2026	https://conductscience.org/library/papers/42919442	PubMed
42,903,681	From CAF subtypes to clinically relevant states: cancer-associated fibroblasts in pancreatic ductal adenocarcinoma.	Front Immunol	2026	https://conductscience.org/library/papers/42903681	PubMed
42,889,240	Testing cellular provenance in the cancer extracellular matrix.	Front Cell Dev Biol	2026	https://conductscience.org/library/papers/42889240	PubMed
42,803,439	ShadoNet: a cell detection and classification framework for Ki-67 pathology images.	Bioinformatics	2026	https://conductscience.org/library/papers/42803439	PubMed
42,794,986	Combination Immunotherapy in Pancreatic Cancer: Current Clinical Evidence and Mechanistic Rationale for Overcoming a "Cold" Tumor.	Cancers (Basel)	2026	https://conductscience.org/library/papers/42794986	PubMed
42,777,708	CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer.	Cell	2026	https://conductscience.org/library/papers/42777708	PubMed
42,730,981	The spatial architecture of tumor immunity: Emerging predictive biomarkers across cancer.	Immunol Res	2026	https://conductscience.org/library/papers/42730981	PubMed
42,724,322	Advances in nanotechnology for early cancer diagnosis: emerging nanoplatforms and multimodal imaging approaches.	Am J Cancer Res	2026	https://conductscience.org/library/papers/42724322	PubMed

1 to 10 of 267

See all 267 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34644529

GET https://conductscience.org/api/papers/v1/34644529/authors?page=2

API reference For AI assistants